WuXi AppTec Stock Surges on Strong Q1 Earnings and CRDMO Demand Growth 
Alphabet Earnings Surge on AI Growth, Cloud Revenue, and Strong Search Performance 
AstraZeneca Q1 2026 Earnings Surge on Strong Oncology and Rare Disease Drug Sales 
Novartis Q1 2026 Earnings Miss Expectations as Generic Competition Pressures Sales 
DeepSeek Slashes AI Model Pricing to Boost Adoption and Challenge Global Rivals 
Advantest Stock Falls on Weak Outlook Despite Strong AI-Driven Results 
TSMC Exits Arm Holdings with $231 Million Share Sale Amid Strategic Portfolio Shift 
Ford Q1 Earnings Beat Expectations, Stock Surges on Strong Guidance 
Robinhood Q1 Earnings Miss Expectations, Stock Drops After Hours 
OpenAI Faces Revenue Pressure and User Growth Challenges Ahead of IPO 
Microsoft Azure Growth Forecast Beats Expectations Amid Rising AI Competition 
China’s Ultra-Cheap EV Boom: Why Electric Cars Cost Far Less Than in the U.S. 
Seagate Stock Surges After Strong Q3 Earnings Beat and Bullish Outlook 
Air Liquide Q1 Revenue Misses Estimates Amid Currency and Energy Headwinds 
Starbucks Raises 2026 Outlook as Turnaround Strategy Boosts Sales and Earnings 
Lightelligence IPO Soars Over 400% in Hong Kong Debut Amid Rising AI Investment Demand 
TEL AVIV, Israel, Feb. 02, 2016 -- Alcobra Ltd. (Nasdaq:ADHD), an emerging pharmaceutical company focused on the development of new medications to help patients with cognitive disorders, including Attention Deficit Hyperactivity Disorder (ADHD) and Fragile X Syndrome, today announced that it will report its financial results for the fourth quarter and fiscal year ended December 31, 2015 before the market open, and will host a corporate update conference call and webcast on Wednesday, February 17 at 8:30 am Eastern Time.
| Conference Call & Webcast | |
| Wednesday, February 17, 2016 @ 8:30am Eastern Time | |
| Domestic: | 855-469-0611 |
| International: | 484-756-4341 |
| Passcode: | 34475008 |
| Webcast: | http://www.alcobra-pharma.com/events.cfm |
| Replays available through March 2, 2016 | |
| Domestic: | 855-859-2056 |
| International: | 404-537-3406 |
| Passcode: | 34475008 |
About Alcobra
Alcobra Ltd. is an emerging pharmaceutical company primarily focused on the development and commercialization of a proprietary drug candidate, MDX, to treat cognitive disorders including ADHD and FXS. For more information please visit the Company's website, www.alcobra-pharma.com, the content of which is not incorporated herein by reference.
U.S. Investor Contacts LifeSci Advisors, LLC Michael Rice 646-597-6979 [email protected] Media Inquiries Sam Brown, Inc. Mike Beyer 773-463-4211 [email protected] Israel Investor Contact: Alcobra Investor Relations Debbie Kaye +972-72 2204661 [email protected]
